IP Library Granted Patent US 8,962,324
Granted Patent B2
US 8,962,324 · App. 13/916,803 · Granted Feb 24, 2015

Method and system for treatment of biological tissue

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,962,324
App. No.
13/916,803
Granted
Feb 24, 2015
Kind
B2
Abstract

A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component and a bioactive agent component. In a preferred embodiment, the ECM scaffold component comprises mesothelial tissue and the bioactive agent comprises a statin.

Claims (5)

1. A composition for treating damaged biological tissue, comprising:

an extracellular matrix (ECM) composition comprising a bioremodelable component comprising acellular mesothelial tissue, said mesothelial tissue further comprising an exogenously added statin, said statin being linked to said mesothelial tissue, wherein, when said ECM composition is administered to damaged biological tissue, said statin interacts with said mesothelial tissue, wherein said ECM composition modulates inflammation of said damaged biological tissue and induces bioremodeling and regeneration of new biological tissue.

2. The composition of claim 1 , wherein said ECM composition further comprises a fluidizing component selected from the group consisting of water and saline.

3. The composition of claim 1 , wherein said statin is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.

4. The composition of claim 1 , wherein, when said ECM composition is administered to damaged cardiovascular tissue, said statin interacts with said mesothelial tissue, wherein myofibroblast and stem cell migration is induced, differentiation of said stem cells into cardiomyocytes is induced, RhoA activation is restricted and matrix metalloprotinase (MMP) production is reduced in said cardiovascular tissue, wherein said ECM composition induces neovascularization and bioremodeling of said cardiovascular tissue.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2025
From: CORMATRIX CARDIOVASCULAR, INC.
To: CORVIVO CARDIOVASCULAR, INC.
Reel/Frame 070481/0747 →
RELEASE OF SECURITY INTEREST Recorded Jun 2, 2017
From: MIDCAP FINANCIAL TRUST
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 042669/0559 →
SECURITY INTEREST Recorded Sep 30, 2015
From: CORMATRIX CARDIOVASCULAR, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 036732/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2013
From: MATHENY, ROBERT G
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 030605/0325 →